Drug intelligence / Profile preview

TV-100

Development stage: Preclinical
Lead developer: TheraVac Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

TV-100 is a monoclonal antibody in preclinical development by TheraVac Biologics. It is designed as an inflammasome-blocking agent, intended to inhibit the activation of the inflammasome complex. By blocking the inflammasome, the drug aims to prevent the maturation and secretion of pro-inflammatory cytokines, which are key drivers in various inflammatory and neurodegenerative diseases. While TheraVac's other pipeline assets, such as TV-301 and TV-202, are virus-like particle (VLP) vaccines targeting specific components like NLRP3 and ASC, the specific molecular target for TV-100 has not been explicitly disclosed beyond its general classification as an inflammasome blocker.

Targets

Inflammasome (Inflammasomes)

Beyond the preview

Go deeper on TV-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TV-100.

Explore the full profile